Measure Twice, Cut Once: Therapeutic Editing of HSPCs Requires Precise Planning.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30951659.
- Also identified by DOI 10.1016/j.stem.2019.03.001.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hematologic diseases may be among the first clinical targets for therapeutic gene editing. In this issue of Cell Stem Cell, Schiroli et al. (2019) report a thorough, unbiased investigation of the impact of gene editing on hematopoietic stem and progenitor function and offer a clear path forward for editing in multiple tissues and conditions.
Medical subject headings
- Gene Editing
- Tumor Suppressor Protein p53